Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Front Immunol ; 12: 789145, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34975884

RESUMO

Chagas' disease is a zoonotic parasitic ailment now affecting more than 6 million people, mainly in Latin America. Its agent, the protozoan Trypanosoma cruzi, is primarily transmitted by endemic hematophagous triatomine insects. Transplacental transmission is also important and a main source for the emerging global expansion of this disease. In the host, the parasite undergoes intra (amastigotes) and extracellular infective (trypomastigotes) stages, both eliciting complex immune responses that, in about 70% of the cases, culminate in permanent immunity, concomitant with the asymptomatic presence of the parasite. The remaining 30% of those infected individuals will develop a syndrome, with variable pathological effects on the circulatory, nervous, and digestive systems. Herein, we review an important number of T. cruzi molecules, mainly located on its surface, that have been characterized as immunogenic and protective in various experimental setups. We also discuss a variety of parasite strategies to evade the complement system - mediated immune responses. Within this context, we also discuss the capacity of the T. cruzi infective trypomastigote to translocate the ER-resident chaperone calreticulin to its surface as a key evasive strategy. Herein, it is described that T. cruzi calreticulin inhibits the initial stages of activation of the host complement system, with obvious benefits for the parasite. Finally, we speculate on the possibility to experimentally intervene in the interaction of calreticulin and other T. cruzi molecules that interact with the complement system; thus resulting in significant inhibition of T. cruzi infectivity.


Assuntos
Antiprotozoários/farmacologia , Doença de Chagas/tratamento farmacológico , Interações Hospedeiro-Parasita/imunologia , Evasão da Resposta Imune/efeitos dos fármacos , Trypanosoma cruzi/imunologia , Antiprotozoários/uso terapêutico , Calreticulina/metabolismo , Doença de Chagas/imunologia , Doença de Chagas/parasitologia , Ativação do Complemento/efeitos dos fármacos , Ativação do Complemento/imunologia , Proteínas do Sistema Complemento/metabolismo , Humanos , Ligação Proteica/efeitos dos fármacos , Ligação Proteica/imunologia , Proteínas de Protozoários/metabolismo , Trypanosoma cruzi/metabolismo
2.
Front Immunol ; 11: 572562, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33240263

RESUMO

Properdin (P) is a positive regulatory protein that stabilizes the C3 convertase and C5 convertase of the complement alternative pathway (AP). Several studies have suggested that properdin can bind directly to the surface of certain pathogens regardless of the presence of C3bBb. Saprophytic Leptospira are susceptible to complement-mediated killing, but the interaction of properdin with Leptospira spp. has not been evaluated so far. In this work, we demonstrate that properdin present in normal human serum, purified properdin, as well as properdin oligomers P2, P3, and P4, interact with Leptospira. Properdin can bind directly to the bacterial surface even in the absence of C3b. In line with our previous findings, AP activation was shown to be important for killing non-pathogenic L. biflexa, and properdin plays a key role in this process since this microorganism survives in P-depleted human serum and the addition of purified properdin to P-depleted human serum decreases the number of viable leptospires. A panel of pathogenic L.interrogans recombinant proteins was used to identify putative properdin targets. Lsa30, an outer membrane protein from L. interrogans, binds to unfractionated properdin and to a lesser extent to P2-P4 properdin oligomers. In conclusion, properdin plays an important role in limiting bacterial proliferation of non-pathogenic Leptospira species. Once bound to the leptospiral surface, this positive complement regulatory protein of the AP contributes to the formation of the C3 convertase on the leptospire surface even in the absence of prior addition of C3b.


Assuntos
Complemento C3b/metabolismo , Fator B do Complemento/metabolismo , Leptospira interrogans/fisiologia , Leptospira/fisiologia , Leptospirose/metabolismo , Properdina/metabolismo , Proteínas da Membrana Bacteriana Externa/metabolismo , Processos de Crescimento Celular , Via Alternativa do Complemento , Citotoxicidade Imunológica , Humanos , Leptospira/patogenicidade , Leptospira interrogans/patogenicidade , Leptospirose/imunologia , Properdina/imunologia , Ligação Proteica , Virulência
3.
Front Immunol ; 11: 1561, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32793217

RESUMO

Because of its capacity to increase a physiologic inflammatory response, to stimulate phagocytosis, to promote cell lysis and to enhance pathogen immunogenicity, the complement system is a crucial component of both the innate and adaptive immune responses. However, many infectious agents resist the activation of this system by expressing or secreting proteins with a role as complement regulatory, mainly inhibitory, proteins. Trypanosoma cruzi, the causal agent of Chagas disease, a reemerging microbial ailment, possesses several virulence factors with capacity to inhibit complement at different stages of activation. T. cruzi calreticulin (TcCalr) is a highly-conserved, endoplasmic reticulum-resident chaperone that the parasite translocates to the extracellular environment, where it exerts a variety of functions. Among these functions, TcCalr binds C1, MBL and ficolins, thus inhibiting the classical and lectin pathways of complement at their earliest stages of activation. Moreover, the TcCalr/C1 interaction also mediates infectivity by mimicking a strategy used by apoptotic cells for their removal. More recently, it has been determined that these Calr strategies are also used by a variety of other parasites. In addition, as reviewed elsewhere, TcCalr inhibits angiogenesis, promotes wound healing and reduces tumor growth. Complement C1 is also involved in some of these properties. Knowledge on the role of virulence factors, such as TcCalr, and their interactions with complement components in host-parasite interactions, may lead toward the description of new anti-parasite therapies and prophylaxis.


Assuntos
Calreticulina/imunologia , Complemento C1/imunologia , Interações Hospedeiro-Parasita/imunologia , Parasitos/patogenicidade , Animais , Ativação do Complemento , Humanos , Evasão da Resposta Imune , Parasitos/imunologia , Trypanosoma cruzi/imunologia , Trypanosoma cruzi/patogenicidade , Fatores de Virulência/imunologia
4.
Front Immunol, v. 11, 572562, nov. 2020
Artigo em Inglês | Sec. Est. Saúde SP, SESSP-IBPROD, Sec. Est. Saúde SP | ID: bud-3368

RESUMO

Properdin (P) is a positive regulatory protein that stabilizes the C3 convertase and C5 convertase of the complement alternative pathway (AP). Several studies have suggested that properdin can bind directly to the surface of certain pathogens regardless of the presence of C3bBb. Saprophytic Leptospira are susceptible to complement-mediated killing, but the interaction of properdin with Leptospira spp. has not been evaluated so far. In this work, we demonstrate that properdin present in normal human serum, purified properdin, as well as properdin oligomers P2, P3, and P4, interact with Leptospira. Properdin can bind directly to the bacterial surface even in the absence of C3b. In line with our previous findings, AP activation was shown to be important for killing non-pathogenic L. biflexa, and properdin plays a key role in this process since this microorganism survives in P-depleted human serum and the addition of purified properdin to P-depleted human serum decreases the number of viable leptospires. A panel of pathogenic L. interrogans recombinant proteins was used to identify putative properdin targets. Lsa30, an outer membrane protein from L. interrogans, binds to unfractionated properdin and to a lesser extent to P2-P4 properdin oligomers. In conclusion, properdin plays an important role in limiting bacterial proliferation of non-pathogenic Leptospira species. Once bound to the leptospiral surface, this positive complement regulatory protein of the AP contributes to the formation of the C3 convertase on the leptospire surface even in the absence of prior addition of C3b.

5.
Sci Rep ; 6: 19300, 2016 Jan 13.
Artigo em Inglês | MEDLINE | ID: mdl-26758086

RESUMO

Blood-feeding insects inject potent salivary components including complement inhibitors into their host's skin to acquire a blood meal. Sand fly saliva was shown to inhibit the classical pathway of complement; however, the molecular identity of the inhibitor remains unknown. Here, we identified SALO as the classical pathway complement inhibitor. SALO, an 11 kDa protein, has no homology to proteins of any other organism apart from New World sand flies. rSALO anti-complement activity has the same chromatographic properties as the Lu. longipalpis salivary gland homogenate (SGH)counterparts and anti-rSALO antibodies blocked the classical pathway complement activity of rSALO and SGH. Both rSALO and SGH inhibited C4b deposition and cleavage of C4. rSALO, however, did not inhibit the protease activity of C1s nor the enzymatic activity of factor Xa, uPA, thrombin, kallikrein, trypsin and plasmin. Importantly, rSALO did not inhibit the alternative or the lectin pathway of complement. In conclusion our data shows that SALO is a specific classical pathway complement inhibitor present in the saliva of Lu. longipalpis. Importantly, due to its small size and specificity, SALO may offer a therapeutic alternative for complement classical pathway-mediated pathogenic effects in human diseases.


Assuntos
Inativadores do Complemento/farmacologia , Via Clássica do Complemento/efeitos dos fármacos , Proteínas de Insetos/farmacologia , Psychodidae/imunologia , Psychodidae/metabolismo , Saliva/metabolismo , Animais , Cromatografia Líquida de Alta Pressão , Ativação do Complemento/efeitos dos fármacos , Complemento C1/antagonistas & inibidores , Complemento C1/imunologia , Complemento C1/metabolismo , Complemento C4/antagonistas & inibidores , Complemento C4/imunologia , Complemento C4/metabolismo , Humanos , Proteínas Recombinantes/farmacologia
6.
Trends Parasitol ; 27(3): 115-22, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21288773

RESUMO

Calreticulin (CRT) from vertebrates is a calcium-binding protein present mainly in the endoplasmic reticulum (ER). There, it directs the conformation of proteins and controls calcium levels. This review will focus on several extracellular roles of Trypanosoma cruzi CRT (TcCRT) in relation to its capacity to inhibit the complement system, mediate parasite infectivity, interfere with angiogenesis and, as a possible consequence, with tumor growth. The TcCRT antiangiogenic effect parallels with the capacity of T. cruzi infection to inhibit tumor development in vivo. Thus, the TcCRT, complement, and endothelial cell interactions seem to be an evolutionary adaptation to promote prolonged parasite-host relationships.


Assuntos
Adaptação Fisiológica/fisiologia , Calreticulina/metabolismo , Interações Hospedeiro-Parasita , Trypanosoma cruzi/patogenicidade , Animais , Trypanosoma cruzi/metabolismo
7.
Immunobiology ; 216(1-2): 265-73, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-20472323

RESUMO

In Trypanosoma cruzi, calreticulin (TcCRT) translocates from the endoplasmic reticulum (ER) to the area of flagellum emergence. We propose herein that the parasite uses this molecule to capture complement C1, in an infective apoptotic mimicry strategy. Thus, TcCRT/C1 interactions, besides inhibiting the classical pathway of complement activation as previously shown in our laboratories, will also promote infectivity. This fact correlates with significant increases in TcCRT mRNA levels during early infection stages of a VERO cell line. In vitro, the collagenous and globular C1q domains simultaneously bind TcCRT and antigen aggregated Igs, respectively. Accordingly, mouse immunizations with TcCRT induced humoral responses that, after challenge, correlated with increased parasitemia. Thus, on the parasite surface, whole Igs anti-TcCRT promote C1 deposits on trypomastigotes while, as expected, F(ab')2 fragments decrease it. Likewise, pretreatment of the parasites with whole anti-TcCRT antibodies augmented parasitemia and mortality in mice. In contrast, pretreatment with F(ab')2 fragments anti-TcCRT, devoid of their capacity to provide additional C1q binding sites, was protective. Most important, while pretreatment of trypomastigotes with C1q increased infectivity in the RAW murine cell line, as well as mice mortality and parasitemia, the F(ab')2 fragments significantly interfered with the C1q-dependent infectivity. Differently from other surface molecules involved in infectivity, TcCRT uses C1 as an adaptor molecule to recognize host cells. As expected, since TcCRT is one of several cell surface parasite molecules participating in infectivity, attempts to interfere with the C1/TcCRT interactions with F(ab')2 fragments, were moderately but significantly effective, both in vitro and in vivo.


Assuntos
Complemento C1/metabolismo , Macrófagos/metabolismo , Trypanosoma cruzi/fisiologia , Animais , Complexo Antígeno-Anticorpo/metabolismo , Antígenos de Protozoários/imunologia , Calreticulina/imunologia , Linhagem Celular , Doença de Chagas , Complemento C1/imunologia , Imunidade Humoral , Imunização , Macrófagos/imunologia , Macrófagos/parasitologia , Macrófagos/patologia , Camundongos , Parasitemia , Ligação Proteica/imunologia , Trypanosoma cruzi/patogenicidade , Virulência
8.
Mol Immunol ; 47(7-8): 1516-21, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20153898

RESUMO

Trypanosoma cruzi (T. cruzi), the agent of Chagas' disease, the sixth most important neglected tropical disease worldwide, causes 50,000 deaths per year in Latin America. T. cruzi calreticulin (TcCRT), a highly pleiotropic chaperone molecule, plays important roles in several host/parasite interactions. Among other functions, we have previously shown that TcCRT, translocated from the endoplasmic reticulum to the area of flagellar emergence, binds human C1q and inhibits activation of the classical pathway in vitro. Based on a series of in vitro experiments, we propose here two mechanisms to explain how TcCRT inhibits the classical pathway at the initial stages of C1 (q, r, s) activation. First, TcCRT interacts in vitro with both solid phase bound active C1s and C1, but impairment of C4 activating capacity is evident only when the serine proteases are within the structural context of the macromolecular first component. Although C1s activity, in this context, is inhibited by TcCRT, the serine protease is not displaced from the C1 complex. Second, TcCRT prevents C1 formation, by interfering with the ability of the (C1r-C1s)(2) tetramer to bind C1q. These complement inhibitory effects are better explained by direct interaction of the parasite protein with C1, rather than by the TcCRT capacity to bind calcium, an essential element for the functional integrity of C1.


Assuntos
Calreticulina/imunologia , Proteínas do Sistema Complemento/imunologia , Proteínas de Protozoários/imunologia , Trypanosoma cruzi/imunologia , Animais , Cálcio/metabolismo , Calreticulina/metabolismo , Ativação do Complemento , Proteínas do Sistema Complemento/metabolismo , Humanos , Ligação Proteica , Proteínas de Protozoários/metabolismo , Serina Proteases/metabolismo , Trypanosoma cruzi/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA